Alliance Pharmaceuticals

Avonbridge House, Bath Road, Chippenham, Wiltshire, SN15 2BB
Telephone: +44 (0)1249 466 966
Fax: +44 (0)1249 466 977
WWW: http://www.alliancepharma.co.uk
Medical Information e-mail: medinfo@alliancepharma.co.uk
Summary of Product Characteristics last updated on the eMC: 10/02/2009
SPC Lysovir 100mg Capsules

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 10/02/2009 and displayed until Current
Reasons for adding or updating:
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 6.1 - List of Excipients
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   04-Feb-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



3.             Pharmaceutical form

Reddish-brown hard gelatin capsules, printed SYMM in white on both the cap and body.

 

4.4.    Special warnings and precautions for use

A similar syndrome has also been reported rarely following withdrawal of amantadine and other anti-Parkinson agents in patients who were not taking concurrent psychoactive medication.

 

4.8     Undesirable effects

         neuroleptic malignant-like syndrome

 

6.1     List of excipients

red iron oxide (E172).  White printing ink: Opacode S-1-7020 containing, Shellac, I.M.S. 74 OP, purified water, soya lecithin (E322), 2-ethoxyethanol, antifoam DC 1510, titanium dioxide (E171).

Updated on 10/08/2005 and displayed until 10/02/2009
Reasons for adding or updating:
  • Change to section 3 - pharmaceutical form
  • Change to section 6.1 - List of Excipients
  • Change to section 10 (date of (partial) revision of the text
Updated on 01/09/2004 and displayed until 10/08/2005
Reasons for adding or updating:
  • Change to section 3 - pharmaceutical form
  • Change to section 10 (date of (partial) revision of the text
Updated on 16/07/2001 and displayed until 01/09/2004
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 01/03/2000 and displayed until 16/07/2001
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   amantadine hydrochloride


© 2010 Datapharm Communications Ltd

Go to www.medicines.org.uk